Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20231902 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kim D, et al. (2010) Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PLoS One 5, e9616 20231902
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T117-p - MST2 (human)
Orthologous residues
MST2 (human): T117‑p, MST2 (mouse): T117‑p, MST2 (rat): T117‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial), COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) transfection of constitutively active enzyme, transfection of dominant-negative enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum starvation decrease
IGF-1 increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited, intracellular localization, phosphorylation
 Effect of modification (process):  carcinogenesis, induced, cell growth, altered
 Comments:  inhibits MST2 T180 autophosphorylation
Associated Diseases
Diseases: Alterations: Comments:
breast cancer increased

T180-p - MST2 (human)
Orthologous residues
MST2 (human): T180‑p, MST2 (mouse): T180‑p, MST2 (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  COS (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MST2 (human) activation of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
staurosporine increase
staurosporine Akt1 (human) inhibit treatment-induced increase constitutively active Akt
IGF-1, staurosporine decrease
LY294002 IGF-1, staurosporine inhibit treatment-induced decrease
LY294002 increase
API-2 increase
Z-VAD-FMK API-2 inhibit treatment-induced increase
doxorubicin increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, protein processing
 Effect of modification (process):  apoptosis, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.